伊文思兰改造多肽用于诊疗一体化的临床转化研究进展

Clinical Translational Research of Evans Blue Modified Peptides Used for Theranostics

肽受体放射性核素治疗(peptide receptor radionuclide therapy,PRRT)是利用放射性核素标记的多肽与肿瘤细胞表面受体进行特异性结合,从而发挥射线的辐射生物效应。近年来,如何进一步提高PRRT药物的疗效一直是国际研究热点。伊文思兰(Evans blue)可与血浆中的白蛋白可逆性结合,故将伊文思兰加入多肽结构可延长放射性药物在血液中的清除时间,改变药代动力学,提高PRRT疗效。本文将围绕伊文思兰改造多肽用于诊疗一体化的临床转化研究进行概述。

Peptide receptor radionuclide therapy(PRRT)specifically uses radiolabeled peptides as bio⁃logical targeting vectors designed to deliver cytotoxic levels of radiation dose to cancer cells that overexpress spe⁃cific receptors.In recent years,how to further improve the efficacy of radiotherapeutic drugs for PRRT has been an international research hotspot.The peptides with Evans blue motif,uses endogenous albumin as a re⁃versible carrier to effectively extend the half⁃life in the blood and substantially increase targeted accumulation and retention within the tumor to achieve better efficacy.This review focuses on the clinical translational re⁃search of Evans blue modified peptides used for theranostics.